ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2507

IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil

Frederico Pinheiro1, Cristina Orikaza2, Gerson Keppeke3, Emília Sato2 and Alexandre de Souza4, 1Universidade Federal de Sao Paulo - UNIFESP, São Paulo, SP, Brazil, 2Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 3Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, 4UNIFESP-EPM, São Paulo, SP, Brazil

Meeting: ACR Convergence 2024

Keywords: Demographics, IgG4 Related Disease, immunology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic, fibroinflammatory condition affecting almost all organs. It is a rare entity that is continuously being studied worldwide. It is considered an autoimmune disease that, in addition to the predominance of IgG4 serum elevation in most patients, has some unique immune cell abnormalities, such as the elevation of plasmablast and signaling lymphocytic activation molecule family member 7-positive (SLAMF7+) cytotoxic effector memory T cells (CD4+ cytotoxic T cells – CTL). In this study, we aimed to delve deeper into the demographic/clinical characteristics and cell profiles of patients with definite or probable diagnoses of IgG4-RD.

Methods: The patients were recruited between 2012 and 2023 at a tertiary single center in Sao Paulo, Brazil. Patients were classified using the 2019 ACR/EULAR Classification Criteria of IgG4-RD as definite or probable. The immunological cell profile in the peripheral blood of patients was compared with that of healthy individuals using flow cytometry.

Results: Among 24 patients with IgG4-RD, 22 had definite and two probable diagnoses and were compared with 24 healthy control subjects, paired by sex and age. Demographic features are shown in Table 1. Notably, a clear predominance of females was related to a more significant proportion of patients with head and neck-limited disease (i.e., 11 patients – nine female and two male patients). Around 80% of patients had multi-organ disease and had a higher IgG4-RD responder index. Almost half of the patients were treated with glucocorticoids and rituximab. The most frequent organ involvement were lymph nodes (70%) and orbits (66%) (Table 2). In the immunological evaluation (Table 3), there were a higher number of B cells in healthy control subjects versus patients (225.3 vs. 127.2, p=0.024), transitional B cells (53.3 vs. 32.2, p=0.017), memory B cells (51.4 vs. 22.1, p=0.004), naïve CD4+ T cells (145.7 vs. 69.7, p=0.019), and percentage of naïve CD8+ T cells (43.4 vs. 33.8, p=0.044). In contrast, IgG4-RD patients had a higher percentage of effector memory CD4+ T cells (23.1 vs. 18.2, p=0.002), a percentage of plasmablasts (8.74 vs. 3.1, p=0.048), and a percentage of T CD4+ SLAMF7+ (18.4 vs. 8.6, p=0.001).

Conclusion: We found a clear female predominance in patients with the head and neck-limited phenotype. Although a significant portion of the IgG4-RD patients received rituximab treatment, there was a higher percentage of plasmablasts and T CD4+ SLAMF7+ cells. These findings suggest the potential value of including these immunological evaluations in patient follow-up. However, it is crucial to underscore the need for additional studies to fully understand the worldwide prevalence of IgG4-RD, emphasizing the importance of the immunological patient’s profile.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: F. Pinheiro: None; C. Orikaza: None; G. Keppeke: None; E. Sato: None; A. de Souza: None.

To cite this abstract in AMA style:

Pinheiro F, Orikaza C, Keppeke G, Sato E, de Souza A. IgG4-related Disease Features and Immunological Profile in a Tertiary Center in Sao Paulo-Brazil [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/igg4-related-disease-features-and-immunological-profile-in-a-tertiary-center-in-sao-paulo-brazil/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/igg4-related-disease-features-and-immunological-profile-in-a-tertiary-center-in-sao-paulo-brazil/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology